Oncofertility, Osteonecrosis Emerge as Patient Concerns

Supportive care is a crucial component of personalized oncology care.

Oncology Live   >   Specialty Focus

John Theurer Cancer Center at Hackensack University Medical Center: Providing Extraordinary Care to the Community

Year after year, the John Theurer Cancer Center (JTCC) harnesses the newest technologies and retains world-class oncologists, nurses, and scientists to fulfill its mission of delivering extraordinary care to patients in the community.

Oncology & Biotech News   >   Academy

Breast Cancer is Diagnosed Later in Men but Is Less Often Fatal

New data show that while men are diagnosed with breast cancer at a mere fraction of the rate of women, they tend to have more advanced disease at the time of diagnosis.

Oncology & Biotech News   >   Clinical Trial Reports

Radiation Therapy After Surgery Shows No Survival Benefit for Elderly Lung Cancer Patients

Many older patients with stage III lung cancer who received radiation therapy fared no better than those who did not receive radiation therapy.

  >   Web Exclusives

Anastrozole Plus Fulvestrant Improved Survival in Metastatic Hormone Receptor-Positive Breast Cancer

The combination of anastrozole and fulvestrant improved survival when used as first-line therapy in postmenopausal women with metastatic HR-positive breast cancer compared with anastrozole alone.

Oncology & Biotech News   >   Conference Highlights

Clinical Endocrinology Conference Coverage Coming Soon

Conference coverage from the 2012 Clinical Endocrinology conference offered by Massachusetts General Hospital, at the Fairmont Copley Plaza Hotel.

Conferences   >   Clinical Endocrinology 2012

Looking Forward: Experts Discuss Exciting Trends in 2012 Oncology Drug Pipeline

Pharmaceutical companies are investing billions of dollars and have more than 900 cancer medications in the pipelines.

Oncology Live   >   Cover Story

Peripheral Neuropathy Profile More Favorable With Eribulin

Patients with metastatic breast cancer who were treated with eribulin mesylate were less likely to experience peripheral neuropathy.

Oncology Live   >   Conference Highlights

Radiation Added to Hormone Therapy Bests Hormone Therapy Alone for High-Risk Prostate Cancer

Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.

Oncology & Biotech News   >   Clinical Trial Reports

Role of Bisphosphonate Therapy Refined but Still More Questions

The developing theme is that bisphosphonates are most effective in postmenopausal patients with HR-positive breast cancer.

Oncology & Biotech News   >   Conference Highlights

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

  >   Web Exclusives

Transplant Recipients Have Higher Risk of Diverse Cancers

Patients who receive a solid organ transplant have about twice the risk of developing cancer as the general population.

Oncology & Biotech News   >   Clinical Trial Reports

Targeted Therapies Yield Most Promising Results: A New Era in Melanoma Treatment Has Begun

Melanoma is one of the most frequent cancers; more than 2 million Americans are treated for skin cancer annually.

Oncology & Biotech News   >   Feature Article

Electronic Ordering System Improves Chemotherapy Care

Human errors can cause higher-than-expected medication error rates and delays in getting the proper chemotherapy doses to the patients who need them.

Oncology Live   >   Specialty Focus

Addition of Bevacizumab May Help in Nasopharyngeal Cancer

Researchers are reporting favorable early results with the addition of bevacizumab to conventional chemoradiation in patients with advanced nasopharyngeal cancer.

Oncology Live   >   Specialty Focus

The Prostate Cancer Microenvironment: Implications for Therapy

In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.

Oncology & Biotech News   >   Conference Highlights

Concurrent Zoledronic Acid Is Preferable in Letrozole-Treated Postmenopausal Patients With Breast Cancer

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Oncology & Biotech News   >   Breast Cancer

Lenalidomide Plus Docetaxel: Phase III Results Fall Short

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Oncology Live   >   Specialty Focus

HPV and the Rise of Head and Neck Cancers

Human papillomavirus is perhaps best known as the main cause of cervical cancer, but if recent trends continue, by 2020 HPV will cause more cases of oropharyngeal cancer each year than cervical cancer.

Oncology & Biotech News   >   Feature Article

What Turns a Good Cell Bad? Exploiting the Hallmarks of Cancerous Cells

Hanahan and Weinberg initially outlined 6 hallmarks that they believed were essential to the transformation of normal cells into malignant cancer cells in most, if not all, human cancers.

Oncology Live   >   Pathways